Abbott Laboratories Corporation

Robert W Schoenleber

John W Kebabian

Michael P DeNinno

Biswanath De

John F DeBernardis

Richard J Perner

Michael D Meyer

David M Stout

Fatima Z Basha

Sheela A Thomas

Michael R Michaelides

Paul P Ehrlich

Chi-nung W Hsiao

Yvonne Connolly Martin

Stanley DiDomenico, Jr

James R Campbell

Novel tetracyclic spirobenzazepine compounds of the formula ##STR1## or a pharmaceutically-acceptable salt, amide or ester thereof, which are dopamine D-1 receptor antagonists useful for treating dopamine-related neurological and psychological disorders, cognitive impairment, attention deficit disorders and addictive behavior disorders.

Tetracyclic spirobenzazepine dopamine antagonists

Novel compounds of Formula (I): ##STR1## or pharmaceutically acceptable salts, esters and amides thereof, wherein A is O, C, CH or CH.sub.2, n is 0 or 1, and the dotted line is a single bond when A is O or CH.sub.2 and a double bond when A is CH or when n=0, A is C and

Dopaminergic compounds

Novel compounds which are selective dopamine agonists are useful for treating disorders characterized by abnormal dopamine levels, such as Parkinson's Disease, as well as cardiovascular disorders.

Dopamine agonists

Growing community of inventors

Deerfield, IL, United States of America

Robert W Schoenleber